These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 34994642)

  • 1. Dynamic Changes of Circulating Tumor DNA Predict Clinical Outcome in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
    Weber S; van der Leest P; Donker HC; Schlange T; Timens W; Tamminga M; Hasenleithner SO; Graf R; Moser T; Spiegl B; Yaspo ML; Terstappen LWMM; Sidorenkov G; Hiltermann TJN; Speicher MR; Schuuring E; Heitzer E; Groen HJM
    JCO Precis Oncol; 2021 Nov; 5():1540-1553. PubMed ID: 34994642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC).
    Ricciuti B; Jones G; Severgnini M; Alessi JV; Recondo G; Lawrence M; Forshew T; Lydon C; Nishino M; Cheng M; Awad M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression.
    Giroux Leprieur E; Hélias-Rodzewicz Z; Takam Kamga P; Costantini A; Julie C; Corjon A; Dumenil C; Dumoulin J; Giraud V; Labrune S; Garinet S; Chinet T; Emile JF
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
    Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors.
    van der Leest P; Hiddinga B; Miedema A; Aguirre Azpurua ML; Rifaela N; Ter Elst A; Timens W; Groen HJM; van Kempen LC; Hiltermann TJN; Schuuring E
    Mol Oncol; 2021 Nov; 15(11):2910-2922. PubMed ID: 34449963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
    Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
    Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune related endonucleases and GTPases are not associated with tumor response in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors.
    Ramdani HO; Falk M; Heukamp LC; Schatz S; Tiemann M; Wesseler C; Diehl L; Schuuring E; Groen HJM; Griesinger F
    Pathol Res Pract; 2021 Nov; 227():153651. PubMed ID: 34673351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
    Vega DM; Nishimura KK; Zariffa N; Thompson JC; Hoering A; Cilento V; Rosenthal A; Anagnostou V; Baden J; Beaver JA; Chaudhuri AA; Chudova D; Fine AD; Fiore J; Hodge R; Hodgson D; Hunkapiller N; Klass DM; Kobie J; Peña C; Pennello G; Peterman N; Philip R; Quinn KJ; Raben D; Rosner GL; Sausen M; Tezcan A; Xia Q; Yi J; Young AG; Stewart MD; Carpenter EL; Aggarwal C; Allen J
    JCO Precis Oncol; 2022 Aug; 6():e2100372. PubMed ID: 35952319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC.
    Hellmann MD; Nabet BY; Rizvi H; Chaudhuri AA; Wells DK; Dunphy MPS; Chabon JJ; Liu CL; Hui AB; Arbour KC; Luo J; Preeshagul IR; Moding EJ; Almanza D; Bonilla RF; Sauter JL; Choi H; Tenet M; Abu-Akeel M; Plodkowski AJ; Perez Johnston R; Yoo CH; Ko RB; Stehr H; Gojenola L; Wakelee HA; Padda SK; Neal JW; Chaft JE; Kris MG; Rudin CM; Merghoub T; Li BT; Alizadeh AA; Diehn M
    Clin Cancer Res; 2020 Jun; 26(12):2849-2858. PubMed ID: 32046999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy.
    Thompson JC; Carpenter EL; Silva BA; Rosenstein J; Chien AL; Quinn K; Espenschied CR; Mak A; Kiedrowski LA; Lefterova M; Nagy RJ; Katz SI; Yee SS; Black TA; Singh AP; Ciunci CA; Bauml JM; Cohen RB; Langer CJ; Aggarwal C
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34095713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
    Sun Y; Duan J; Fang W; Wang Z; Du X; Wang X; Li C; Cai S; Zhao J; Li S; Zhang L; Bai H; Wang J
    BMC Med; 2021 Oct; 19(1):239. PubMed ID: 34615542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer.
    Waldeck S; Mitschke J; Wiesemann S; Rassner M; Andrieux G; Deuter M; Mutter J; Lüchtenborg AM; Kottmann D; Titze L; Zeisel C; Jolic M; Philipp U; Lassmann S; Bronsert P; Greil C; Rawluk J; Becker H; Isbell L; Müller A; Doostkam S; Passlick B; Börries M; Duyster J; Wehrle J; Scherer F; von Bubnoff N
    Mol Oncol; 2022 Jan; 16(2):527-537. PubMed ID: 34653314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC.
    Jun S; Shukla NA; Durm G; Hui AB; Cao S; Ganti AK; Jabbour SK; Kunder C; Alizadeh AA; Hanna NH; Diehn M
    J Thorac Oncol; 2024 Oct; 19(10):1427-1437. PubMed ID: 38971369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer.
    Ebert EBF; McCulloch T; Hansen KH; Linnet H; Sorensen B; Meldgaard P
    Lung Cancer; 2020 Mar; 141():37-43. PubMed ID: 31945708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC.
    Cheng ML; Lau CJ; Milan MSD; Supplee JG; Riess JW; Bradbury PA; Jänne PA; Oxnard GR; Paweletz CP
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study.
    Si H; Kuziora M; Quinn KJ; Helman E; Ye J; Liu F; Scheuring U; Peters S; Rizvi NA; Brohawn PZ; Ranade K; Higgs BW; Banks KC; Chand VK; Raja R
    Clin Cancer Res; 2021 Mar; 27(6):1631-1640. PubMed ID: 33355200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized circulating tumor DNA detection to monitor immunotherapy efficacy and predict outcome in locally advanced or metastatic non-small cell lung cancer.
    Cheng L; Gao G; Zhao C; Wang H; Yao C; Yu H; Yao J; Li F; Guo L; Jian Q; Chen X; Li X; Zhou C
    Cancer Med; 2023 Jul; 12(13):14317-14326. PubMed ID: 37184093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer.
    Iijima Y; Hirotsu Y; Amemiya K; Ooka Y; Mochizuki H; Oyama T; Nakagomi T; Uchida Y; Kobayashi Y; Tsutsui T; Kakizaki Y; Goto T; Miyashita Y; Omata M
    Eur J Cancer; 2017 Nov; 86():349-357. PubMed ID: 29078173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
    Li Y; Zhang FS; Guo L; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
    [No Abstract]   [Full Text] [Related]  

  • 20. Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer.
    Tolmeijer SH; van Wilpe S; Geerlings MJ; von Rhein D; Smilde TJ; Kloots ISH; Westdorp H; Coskuntürk M; Oving IM; van Ipenburg JA; van der Heijden AG; Hofste T; Weiss MM; Schalken JA; Gerritsen WR; Ligtenberg MJL; Mehra N
    Eur Urol Oncol; 2024 Apr; 7(2):282-291. PubMed ID: 37673768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.